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ABSTRACT
Background. Resectability of colorectal liver metastasis
(CRLM) depends on major vascular involvement and is
affected by chemotherapy-induced liver injury. Parenchyma-
sparing with combined resection and reconstruction of
involved vessels may expand the indications and safety of
hepatectomy.
Methods. Of 92 patients who underwent hepatectomy for
CRLM, 15 underwent major vascular resection and
reconstruction. The reconstructed vessels were the portal
vein (PV) in five cases, the major hepatic vein (HV) in nine
cases, and the inferior vena cava in six cases.
Results. All PV reconstructions were direct anastomoses.
The HV was reconstructed with an autologous inferior
mesenteric venous patch or an external iliac vein interposi-
tion graft. Total hepatic vascular exclusion was performed
for six patients. Of nine patients with HV reconstruction,
three had tumors involving all three major HVs, in whom the
left HV was reconstructed as an only vein after extended
right hepatectomy. In another six patients, multiple bilobar
tumors or tumors in the liver that had chemotherapy-induced
injury involved one or two HVs. Parenchyma-sparing by
reconstruction of the HV was performed to secure the
residual liver function. The patients with vascular recon-
struction had an operative time of 462 ± 111 min and a
blood loss of 1278 ± 528 mL. No complication classified as
Clavien–Dindo 3 or more developed. The median hospital
stay was 17 days (range 8–26 days). The cumulative 5-year
survival rate for all the patients was 54.6 %, with no sig-
nificant difference according to vascular reconstruction.
Conclusion. Parenchyma-sparing hepatectomy combined
with vascular reconstruction is a useful option to avoid
major hepatectomy among various procedures for resection
of CRLM with major vascular invasion.
Despite recent advances in chemotherapy, surgical resec-
tion remains the only treatment that can ensure long-term
survival for patients with colorectal liver metastases (CRLM).
Major vascular involvement is one of the most common rea-
sons for unresectability. Although a free surgical margin is of
special importance for long-term survival,1–5 major vascular
involvement often is a barrier against curability.
Hepatectomy for CRLM with massive involvement of
portal vein (PV) bifurcation, multiple major hepatic veins
(HVs), or the inferior vena cava (IVC) still is challenging.
Tumors involving all three HVs have been considered
unresectable or even a contraindication for hepatectomy.6
Reconstruction of a single vein of residual liver is required
after major hepatectomy, with combined resection of the
three HVs.7,8
Multiple bilobar tumors are another difficult situa-
tion.5,9,10 When one of the tumors involves a major HV,
major hepatectomy usually is considered. However, the
volume of the residual liver can be insufficient due to the
significant amount of hepatectomy for tumors in the con-
tralateral liver. Even if the tumor is solitary, it is better to
avoid major hepatectomy when the background liver has
been injured with chemotherapy-induced damage. In these
situations, parenchyma-sparing hepatectomy with com-
bined resection and subsequent reconstruction of involved
vessels may be an alternative to major hepatectomy.
Sporadic reports describe hepatectomy with major vas-
cular reconstruction for CRLM.7,8,11–16 Nevertheless, the
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number of patients and the variation of procedures in the
respective reports are limited. Technical aspects, safety,
and the impact on long-term survival are still to be eluci-
dated. Moreover, the concept of parenchyma-sparing
hepatectomy is uncommon in these studies.
The current study aimed to show the specific role of
parenchyma-sparing hepatectomy in various procedures of
combined vascular reconstruction for resection of CRLM
with major vascular involvement.
PATIENTS AND METHODS
Patients
From 2008 to 2014, 313 patients underwent hepatec-
tomy at our hospital. Of these patients, 92 underwent
hepatectomy for CRLM, including 15 patients with major
vascular resection and reconstruction. These 15 patients did
not include patients with simple wedge resection, per-
formed with side-clamping and suturing. The 15 patients
included 2 patients who underwent extensive wedge
resection of the IVC that required total hepatic vascular
exclusion (THVE). Written informed consent for the use of
clinical data for research works in an anonymous setting
was obtained from every patient. The institutional review
board of Nara Prefecture Medical Center Hospital
approved this clinical study.
Indication Criteria for Hepatectomy and Vascular
Reconstruction
Tumor status was evaluated by using three-phase con-
trast-enhanced computed tomography (CT). Contrast-
enhanced magnetic resonance imaging (MRI) was added
when needed. The indication criteria for surgical resection
of CRLM required that there be no severe comorbid sys-
temic condition, no uncontrollable extrahepatic metastases,
curative intent possible for all liver metastases, and a
functional liver remnant exceeding 30 % of the whole
liver. The requirement was affected by the severity of
chemotherapy-induced liver injury, indicated by a blood
chemistry test or the indocyanine green retention rate at
15 min.
Surgical Procedures
The abdomen was opened via a J-shape incision. The
relationship between the tumors and major intrahepatic
vasculatures were confirmed by intraoperative ultrasonog-
raphy. The liver was mobilized as broad as required for the
planned surgery. The hepatic parenchyma was transected
using the clamp-crushing method. Thin vessel branches
were burned by electrocautery. The thicker branches were
ligated and divided. The intermittent Pringle’s maneuver
was applied routinely, involving a 15-min period for
clamping and a 5-min period for release. For vascular
reconstruction, continuous suture was performed princi-
pally with 6-0 or 5-0 prolene. No antithrombotic agent was
administered after surgery regardless of the procedures.
Evaluation of Operative Morbidity and Mortality
The severity of postoperative complications was clas-
sified according to Clavien–Dindo criteria.17 Hepatic
failure was defined as a serum total bilirubin level higher
than 5 mg/dL after postoperative day 5 or later. Operative
mortality was defined as all in-hospital deaths and deaths
within 90 days after surgery.
Follow-up Schedule and Adjuvant Chemotherapy
The patients received CT or MRI evaluation every 4–
6 months after discharge. A blood test and physical
examination were applied every 1–6 months until 5 years
after the last intervention. Of the 15 patients, 9 received
adjuvant chemotherapy after hepatectomy.
Statistical Analysis
The values are shown as mean ± standard deviation or
as median with minimum and maximum values in paren-
thesis. Survival rates for the patients were calculated by the
Kaplan–Meier method and compared by the log-rank test.
A p value lower than 0.05 was considered statistically
significant.
RESULTS
The 15 patients who underwent hepatectomy with major
vascular reconstruction included 9 men and 6 women with
a median age of 69 years (range 36–78 years). The CRLM
was synchronous in seven patients and metachronous in
eight patients. The reconstructed vessels were PV in five
patients, HV in nine patients, and IVC in six patients,
whereas two or three types of vessels were reconstructed at
the same time in some patients (Table 1).
Procedures of Vascular Reconstruction (Table 1)
PV Reconstruction (Cases 1–5 in Table 1) The tumors
were exclusively large (7–16 cm), involving portal bifurca-
tion. Right hepatectomy and direct end-to-end anastomosis
between the portal trunk and the left PV branch was performed
for all the patients. The most important issue during this
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procedure was to judge the necessity of bile duct resection and
subsequent bilioenteric anastomosis. The relation between the
cutting line of the bile duct and the point of biliary bifurcation
was confirmed by intraoperative cholangiography in all the
patients. Although no patients required bilioenteric anasto-
mosis in this series, transient external biliary drainage was
provided for two patients by placement of a C-tube to avoid
stenosis of the sutured site of the biliary stump.
Reconstruction of an Only Vein of the Liver Remnant
(Cases 5–7 in Table 1) Three of nine patients with HV
reconstruction (cases 5–13), had tumors involving all three
major HVs (cases 5–7). Because large dominant tumors
existed in the right liver (diameter 8–20 cm), the left
hepatic vein (LHV) was reconstructed as a single vein of
the liver remnant after extended right hepatectomy with the
middle hepatic vein (MHV). The crafted autologous infe-
rior mesenteric vein (IMV) was used as a patch graft in two
of three patients (cases 5 and 6). In the remaining patient
(case 7, Fig. 1), the autologous external iliac vein graft was
used as an interposition graft and anastomosed between the
proximal stump of the LHV ? MHV trunk and the distal
stump of the LHV as an only drainage route of the residual
liver. In two patients, THVE was applied because the HV
invasion reached its orifice on the IVC.
Parenchyma-Sparing by Reconstruction of the HV
(Cases 8–13 in Table 1) The HV was reconstructed for the
purpose of parenchyma-sparing in these patients instead of
major hepatectomy. The tumors involved one or two of the
three major HVs. Major hepatectomy, including involved
HVs, might be a usual choice in such a situation. However,
most of these patients had multiple bilobar tumors. Because
both a major hepatectomy and a significant amount of
partial hepatectomy of the contralateral liver would have
resulted in an insufficient liver remnant, parenchyma-
sparing by reconstruction of the HV was performed to
avoid major hepatectomy (Fig. 2). Even if the tumor is
unilobar, major hepatectomy should be avoided when the
background liver has been injured by chemotherapy before
surgery (case 13). For two patients in whom involvement
of the HV extended to the IVC, THVE was applied. The
HV was reconstructed by IMV patch grafting in four
patients, and repaired by suturing in the remaining two
patients under THVE.
IVC Reconstruction Under THVE (Cases 14 and 15 in
Table 1) The procedure was applied for the tumor
involving the IVC extensively around the right hepatic vein
(RHV). Although the invasion around the RHV usually can
be repaired by simple suture with side-clamping of the

















1 PV 2 7.0 Right hepatectomy Left PV Direct anastomosis No
2 PV 6 16.0 Right hepatectomy Left PV Direct anastomosis No
3 PV 1 14.3 Right hepatectomy Left PV Direct anastomosis No
4 PV 2 10.0 Right hepatectomy Left PV Direct anastomosis No
5 PV, HV, IVC 2 9.0 Extended right hepatectomy Left PV
LHV




6 HV, IVC 1 20.0 Extended right hepatectomy LHV
IVC
IMV patch for HV Yes (9)




8 HV 4 2.5 Partial 9 4 RHV IMV patch graft No





10 HV, IVC 9 5.5 Segment 8: partial 9 5 RHV, LHV Direct Yes (10)
11 HV 7 5.7 Central bisectionectomy: partial 9 2 RHV IMV patch graft No
12 HV 6 3.5 Partial in segments 58 and 7, segment 1 LHV IMV patch graft No
13 HV 2 3.0 Partial 9 2 MHV IMV patch graft No
14 IVC 10 18.0 Right hepatectomy, segment 3:
partial 9 2
IVC Direct Yes (7)
15 IVC 1 6.0 Right hepatectomy IVC IMV patch Yes (26)
THVE, total hepatic vascular exclusion; PV, portal vein; HV, hepatic vein; IVC, interior vena cava; LHV, left hepatic vein; IMV, inferior
mesenteric vein; RHV, right hepatic vein; MHV, middle hepatic vein
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IVC, the involvement of IVC was so extensive leftward, it
was not possible to apply side-clamping of the IVC in these
patients. Consequently, THVE was needed.
Patency of the Reconstructed Vessels
The patency of the reconstructed vessels was confirmed
by Doppler ultrasonography during the first postoperative
week in all the patients. One patient with LHV recon-
struction using an IMV patch graft as a parenchyma-
sparing procedure without major hepatectomy showed
obstruction of the reconstructed vein without congestion or
ischemia of the liver shown on the CT image 4 months
after surgery. Others showed patent reconstructed vessels
on the follow-up CT.
Operative Parameters, Postoperative Course, and
Long-Term Survival
For 15 patients with vascular reconstruction, the operative
time was 462 ± 111 min, and the blood loss was
1278 ± 528 mL (Table 2). No complication related to vas-
cular reconstruction was observed. No complication classified
as Clavien–Dindo 3 or higher and no operative mortality
occurred. The median hospital stay was 17 days (range 8–
26 days), and all the patients were discharged within 1 month.
The cumulative 5-year survival rate for all 92 patients was
54.6 %. The survival of the patients with and without major
vascular reconstruction did not differ significantly (Fig. 3).
DISCUSSION
The current study showed short- and long-term results of
hepatectomy in combination with major vascular resection
and reconstruction for CRLM. The analysis showed some
patterns of procedure. To save patients, PV reconstruction
for hepatic hilar invasion and HV reconstruction of the
only vein after major hepatectomy for involvement of all of
three major HVs were indispensable methods. Par-
enchyma-sparing by reconstruction of the HV instead of
major hepatectomy was indicated for multiple bilobar
metastases and chemotherapy-induced liver injury.
Although the procedure was sometimes complex, the
operative data and morbidity were acceptable. The long-
term survival rate also was satisfactory compared with the
rates in other studies.18–20
The current study classified the patterns of combined
major vascular resection/reconstruction procedures into
FIG. 1 Extended right hepatectomy with left hepatic vein (LHV)
reconstruction using interposition of an autologous external iliac vein
graft (case 7 in Table 1). Initially, the patient’s tumor condition was
diagnosed as unresectable because of massive multiple tumors
predominantly in the right liver, with invasion of the right hepatic
vein (RHV) and the trunk of the middle hepatic vein (MHV) and LHV
(arrows on a). After seven courses of mFOLFOX6/panitumumab, the
tumors shrank significantly, and the trunk of the MHV ? LHV still
was involved by the tumor (arrow on b). An external iliac vein
interposition graft (asterisk) 5 cm long has been anastomosed
between the distal stump of the LHV (white arrow) and the interior
vena cava (IVC) orifice of the MHV ? LHV trunk (black arrow
on c). A computed tomography (CT) scan 12 months after hepate-
ctomy shows the reconstructed LHV to be patent (asterisk on d). At
this writing, the patient is alive without recurrence 24 months after
the hepatectomy
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four types (see ‘‘Procedures of Vascular Reconstruction’’
section), including parenchyma-sparing hepatectomy. Such
classification of technical variations has not been reported
in other literatures.
For the patients with large tumors involving the hepatic
hilum, PV reconstruction was indicated exclusively with
right hepatectomy. The reason may have been that the right
portal branch was shorter than the left portal branch. The
most important point during this procedure was to set an
accurate cutting line of the bile duct. Although we have not
experienced a case that needs bile duct resection and bil-
ioenteric anastomosis, it should be considered that the
FIG. 2 Partial resection of segments 4 and 8 associated with a large
amount of hepatectomy of the anterior section and segment 7 (case 12 in
Table 1). The ventral wall of the middle hepatic vein (MHV) and the left
hepatic vein (LHV) is involved by the tumor occupying segments 4 and 8
(arrow on a). A significant amount of the anterior section and segment 7
must be resected for other tumors (red dotted lines) (b). The tumor in
segments 4 and 8 was resected with the whole MHV and the anterior wall
of the LHV (asterisk on c). The white arrow shows the remaining pos-
terior wall of the LHV (c). The defect of LHV was reconstructed with an
inferior mesenteric vein (IMV) patch graft stretched between the
proximal orifice of the trunk of MHV ? LHV and the distal orifice of
the LHV, with four points-stay stitches (d). ‘‘Anterior’’ shows the large
defect of the right anterior section (d). ‘‘Lateral’’ shows the left lateral
section spared by LHV reconstruction (d)
TABLE 2 Operative parameters and postoperative course of 15
patients with major vascular reconstruction
Parameters Values or no.
of patients
Mean operation time (min) 462 ± 111



























With vascular reconstruction (n=15)
Those without (n=77)
P=0.3786
FIG. 3 Cumulative overall survival rate after hepatectomy for
colorectal liver metastasis according to major vascular reconstruction.
The survival rate for the 15 patients who underwent hepatectomy with
major vascular reconstruction was compared with that of 77 patients
who did not in the same era. The two groups did not show a
statistically significant difference
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patient may become vulnerable to reflux cholangitis after
bilioenteric anastomosis. This could be important for
CRLM patients who may receive systemic chemotherapy
for adjuvant therapy or recurrence.
When the tumors involve all three major hepatic veins,
HV reconstruction is an only way to indicate curative
hepatectomy. It may be the ultimate parenchyma-sparing
for the last liver remnant. The reports of hepatectomy with
HV reconstruction show only a limited number of patients
who underwent reconstruction of an only vein of the
residual liver.7,8,11,14,21 We experienced three cases of
reconstruction of the LHV as the only vein of the liver
remnant after extended right hepatectomy including RHV,
MHV, and LHV. This procedure was psychologically
challenging because the ischemic time of the liver had to
be shortened, and failure of the reconstruction would be
lethal. Careful planning, fine technique of hepatectomy,
and accurate vascular anastomosis were required for
success.
Parenchyma-sparing with HV reconstruction can be an
alternative to major hepatectomy. The procedure was
indicated mainly for patients with multiple bilobar tumors.
Because nonanatomic hepatectomy does not have a nega-
tive impact on the prognosis for patients with CRLM,2–5
parenchyma-sparing with this procedure may be a useful
option. One report described HV reconstruction in a non-
mandatory setting for patients with multiple bilobar CRLM
based on a concept similar to ours.14
Recently, conversion therapy has been an useful strategy
for initially unresectable CRLM patients, and many
patients have received intensive chemotherapy before
hepatectomy.22,23 Hepatectomy for patients with
chemotherapy-induced liver injury is prone to postopera-
tive morbidity and liver failure.24 In such situations,
parenchyma-sparing hepatectomy with HV reconstruction
may be a choice to avoid major hepatectomy. Of course,
preoperative portal vein embolization (PVE) with subse-
quent major hepatectomy is a simpler approach. However,
PVE induces humoral growth factors that can stimulate
proliferation of colorectal cancer cells and promote recur-
rence of CRLM after hepatectomy.25,26 Although two-stage
hepatectomy and ALPPS (associating liver partition and
portal vein ligation for staged hepatectomy) also may be
possible solutions, the feasibility and safety of these
approaches are subjects of an ongoing debate due to the
high rate of treatment failure and interstage morbidity.9,10
Nevertheless, these methods include major hepatectomy. If
intrahepatic recurrence develops after major hepatectomy,
the methods of hepatectomy are restricted. The advantage
of parenchyma-sparing with HV reconstruction may be
preservation of major vasculatures, which reserves varia-
tion of the hepatectomy procedure in case of future
intrahepatic recurrence. This point is worth considering.
The techniques used for parenchyma-sparing hepatec-
tomy are similar to those reported previously.11,12,14–16
Azoulay et al.15 reported surgical results for 84 consecutive
patients who had 97 vascular reconstruction combined with
liver resection. This is the largest series with this approach.
However, no report has described parenchyma-sparing
with vascular reconstruction to avoid major hepatectomy.
The concept results from recent refinement and stability of
vascular reconstruction techniques. The current study
showed that parenchyma-sparing by vascular reconstruc-
tion can be a dominant choice rather than major
hepatectomy of the involved major vessel side.
The THVE procedure was applied for 6 of 15 patients
without veno-venous bypass because the duration of the
procedure was within 30 min in all cases. Azoulay et al.16
reported in situ hypothermic portal perfusion under veno-
venous bypass to attenuate the ischemic damage of THVE.
The cold ischemic time in their series was approximately
100 min. In the current study, to minimize the duration of
the occlusion, THVE was applied just before cutting of the
IVC, not during hepatic parenchymal transection. These
experiences show that veno-venous bypass is not manda-
tory, in view of the resulting hemodynamics and ischemic
damage, when the duration of THVE is within 30 min.
The selection of the reconstruction method is key to
success. When the major HV branch is resected, direct
anastomosis usually is impossible because the position of
HV was fixed on the liver. In the current study, the inter-
position of autologous external vein grafting was used for
circumferential resection of the HV because it fit in size, as
reported by other investigators.21 The ovarian vein graft
also fits as an interposition graft for the HV (our recent
experience). Regardless of the size of the defect in the HV
or IVC, the crafted IMV was sufficient as a patch graft to
prevent stenosis in the current study. Azoulay et al.15 used
polytetrafluoroethylene (PTPE) vascular grafts for recon-
struction of the resected major HVs and administered
heparin as an anticoagulant treatment in many cases. The
primary policy of the current series was to use autologous
venous graft to avoid anticoagulant treatment. This may
have been one of the reasons why no patient experienced
hemorrhagic complications.
This study was limited by its small sample size. This
could have been the reason why the long-term survival did
not differ significantly between the patients with and
without major vascular reconstruction (Fig. 3). Neverthe-
less, the survival rate for the patients with vascular
reconstruction was not extremely poor. These results
encourage expansion of the indication for hepatectomy
using major vascular resection and reconstruction. Par-
enchyma-sparing hepatectomy with meticulous vascular
reconstruction may become one of the standard procedures
of hepatectomy for advanced CRLM.
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In conclusion, the combined major vascular resection
and reconstruction with hepatectomy for CRLM showed
acceptable short- and long-term results. Parenchyma-spar-
ing hepatectomy to avoid major hepatectomy is a useful
option among various vascular reconstruction procedures
for resection of CRLM with major vascular invasion.
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